The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma?
In this interview, Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, shares updates from the CARTITUDE-4 trial (NCT04181827), which demonstrated an improvement in overall survival (OS) in relapsed/refractory (R/R) patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy compared to the current standard of care. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is going to be also presented in this meeting, in the IMS meeting in Rio de Janeiro next week and it is focusing the presentation on overall survival and also updated the PFS and I can share with you that the overall survival is already significantly better for patients receiving the CAR-T between one and three lines of therapy, as compared to the control therapy that was the standard you said at that time...
This is going to be also presented in this meeting, in the IMS meeting in Rio de Janeiro next week and it is focusing the presentation on overall survival and also updated the PFS and I can share with you that the overall survival is already significantly better for patients receiving the CAR-T between one and three lines of therapy, as compared to the control therapy that was the standard you said at that time. What is my message? My message is that I think now with the CAR-Ts, we have a really similar, also with bispecifics, all the immunotherapy is making really – is opening really, a new avenue for the treatment of patients. Until now, they would use it at relapse, but the data in CARTITUDE is showing that in early relapse, very early relapse, even after one line of therapy, the benefit is significantly better as compared to the standard of care that we can use so far.
Read more...
Disclosures
JSM declares participation on advisory boards and consulting services, on behalf of my Institution, for Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, and SecuraBio.
